A Pharmaceutical Company Is Now One of the Biggest Holders of a DeFi Stablecoin

A pharmaceutical firm quietly accumulated nearly 9% of SKY's total supply — the governance token behind the protocol formerly known as MakerDAO.

This is weird. A pharma company holding a meaningful stake in a DeFi stablecoin protocol. The company hasn't disclosed its strategy, but the position is large enough to influence governance votes on DAI (now USDS) parameters like stability fees and collateral ratios.

The crypto-to-pharma pipeline is not something anyone had on their 2026 bingo card. But it makes a certain kind of sense: SKY generates revenue from stability fees on its stablecoin. If you're a company looking for yield on treasury assets outside the traditional banking system, a stablecoin protocol with predictable cash flows is... not the craziest idea.

Still strange. The intersection of pharmaceutical companies and DeFi governance raises questions about who's actually making decisions about stablecoin monetary policy. When a pharma company can vote on DAI's interest rates, the "decentralized" part of DeFi gets a lot more complicated.

One to watch.